23:12 , Jul 17, 2018 |  BC Extra  |  Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
21:20 , May 11, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Akari

Synlogic Inc. (NASDAQ:SYBX) said President and CEO Jose Carlos Gutiérrez-Ramos has resigned. CMO Aoife Brennan will serve as interim president and CEO while the synthetic biology company seeks a successor. Autoimmune and inflammatory disease company...
23:39 , Mar 9, 2018 |  BC Extra  |  Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received RG6107...
20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
06:32 , Nov 3, 2017 |  BC Week In Review  |  Financial News

Akari raises $17.4M follow-on

On Oct. 18, autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) raised $17.4 million through the sale of 3.5 million ADSs at $5 per share in a follow-on underwritten by Cantor Fitzgerald, William Blair...
23:53 , Sep 21, 2017 |  BC Extra  |  Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria. The announcement appears...
23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
00:30 , Jun 9, 2017 |  BC Extra  |  Company News

Management tracks

Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3. He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH...
23:31 , May 17, 2017 |  BC Extra  |  Company News

Management tracks

Protein therapeutics company Molecular Partners AG (SIX:MOLN) named Patrick Amstutz CEO. Amstutz had been acting CEO since the November 2016 resignation of Christian Zahnd. Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) said CEO...